Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9611MR)

This product GTTS-WQ9611MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9611MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5173MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ11155MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ7888MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ11024MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ9317MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ2602MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ1691MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ8126MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW